Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MDH1 | P40925 | 1/20 | 0.46 |
| ▸ | MDH2 | P40926 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992678 | 0.95 | PPARA (0.56) | PPARADGAT1PPARDMAOBPPARG | |
| SCHEMBL21991326 | 0.91 | MAOB (0.64) | PPARAPPARDMAOBPPARGMRGPRX4 | |
| SCHEMBL21991302 | 0.84 | ALDH1A1 (0.51) | PPARADGAT1PPARDMAOBPPARG | |
| SCHEMBL21991977 | 0.84 | PPARA (0.73) | PPARADGAT1PPARDMAOBPPARG | |
| SCHEMBL21748731 | 0.83 | DGAT1 (0.52) | PPARADGAT1MAOBSMN1; SMN2 | |
| SCHEMBL21991304 | 0.81 | NPC1 (0.51) | PPARAPPARDMAOBPPARGALDH1A1 | |
| SCHEMBL21991543 | 0.81 | PPARA (0.57) | PPARADGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13948414 | 0.81 | CYP2C9 (0.61) | PPARADGAT1PPARGSMN1; SMN2 | |
| SCHEMBL5724626 | 0.80 | PPARA (0.58) | PPARADGAT1PPARG | |
| SCHEMBL21991914 | 0.80 | PPARA (0.45) | PPARADGAT1PPARDMAOBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885DGAT1 525/4885PPARD 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.